Despite the many clinical trials of combination chemotherapy for advanced lung cancer performed to date, the response rate of this tumor to chemotherapy remains fairly low. This is partly due to the limited efficacy of the currently available therapeutic agents for lung cancer and also partly due to the difficulty of selecting suitable drugs for individual patients. Individual tumors of the same histological type vary widely and unpredictably in their response to chemotherapy. Unlike most other carcinomas, lung cancer has manifold histologic characteristics and high level of heterogeneity. Improvement of the prognosis for patients with this cancer will require the development of methods for the rapid and accurate prediction of the response to specific regimens of combination chemotherapy. A number of in vivo or in vitro chemosensitivity tests have been tested for their ability to predict the efficacy of anticancer agents treatment is started1-11). However, these tests have various problems such as a low graft take ratio, a high cost, delayed results, and inaccuracy. Moreover, it is difficult to evaluate the response to combination chemotherapy, which is usually used for adjuvant therapy after surgery. Twenty-six of these specimens, were used for evaluation of the relationship between the assay results and the clinical response.
Administration of anticancer drugs
After tumor transplantation, eggs were incubated at Three regimens commonly used Japan for the treatment of non-small lung cancer were assessed. These were PV therapy (CDDP+VDS), PAM therapy (CDDP+ADM+MMC), and MVP therapy (MMC+ VDS+CDDP). Each drug was injected into the CAM vein together with 0.1ml of 0.9% NaCl. The doses used corresponded to the clinical dose adjusted for body weight ( Table 1) .
Evaluation of anticancer effect
The embryos were killed at 17 days of age, which was 4 days after administration of the drugs and 7 days after tumor transplantation. Tumors were carefully excised from the CAM, washed with 0.9% NaCl, and weighed.
Portions of each tumor were preserved for microscopic examination.
As described by Uchida et al.15) , the growth inhibition ratio was calculated as follows: Inhibition ratio Table 1 Chemotherapy doses used in the assay and in clinical weight of the control group and Wt is that of the treated group.
Clinical treatment and evaluation
The lung cancer patients were administered anticancer drugs without considering the results of this test, and depending on the choice of their own physicians. Postoperative staging was performed by the new international TNM staging system proposed in 198716). Stage I patients or those over 75 years of age were not given postoperative chemotherapy. In addition, patients who received any radiation therapy were excluded from this study. Twenty-six patients in stages II , III A, III B, and IV were treated with the same protocols as those used in the chick embryo assay after the operation and was repeated at 4-week intervals for 2 or 3 courses.
The clinical response to chemotherapy was evaluated from the survival time of the patients after surgery. Operations were classified as curative (the tumor and metastatic lymph nodes were completely removed) and noncurative (the tumor, the metastatic lymph nodes, or both were not completely removed).
As described by Watanabe et al.17) , postoperative chemotherapy was defined as effective when stage IV patients or noncuratively resected patients survived>12 months, when curatively resected stage III patients survived>24 months, or when curatively resected stage II patients survived>36 months. The chemosensitivity test results were classified on the basis of the clinical outcome as true positive (both the chemosensitivity test and the clinical response were positive), false positive (the chemosensitivity test was positive, but no clinical response was obtained), false negative (the chemosensitivity test was negative, but a clinical response was obtained), and true negative (both the chemosensitivity test and the clinical response were negative). 
Results
Tumor growth on the CAM All of the human lung cancers tested grew sufficiently well on the CAM to be weighed (mean 7 days after transplantation.
Epidermoid carcinoma grown on the CAM is shown in Fig. 1 .
Effect of combination chemotherapy on in vitro tumor growth
The evaluation rate was 100%. The efficacy rates of PV, PAM, and MVP therapy for transplanted tumors were 16.9%, 13.8%, and 19.0%, respectively, and these rates were dose-dependent. When doses corresponding to double the clinical dose were tested in this assay, the efficacy rates of PV, PAM, and MVP therapy increased to 22.2%, 28.6%, and 30.8%, respectively. Table 2 Association between the chick embryo assay data and the clinical response of individual lung cancers to combination chemotherapy rates are high for both surgical specimens and for cultured cell lines15). At least in the first generation after transplantation, the tumors histologically resemble the parent tumors21). In this study, the graft take rate was 100% and the histological characteristics of the parent tumors were maintained. According to Ossowski et al., at least within the first generation of transplantation onto the CAM, the malignant nature of the parent tumor is also maintained22 
